Medanta Q2 FY27 Revenue Surges 33.6% to ₹1,469 Crore, Profit Up 38.3%
Global Health Limited (Medanta) reported Q2 FY27 revenue of ₹1,469 crore, up 33.6% YoY. Operating EBITDA rose 60.2% to ₹370.1 crore, and profit after tax increased 38.3% to ₹219.1 crore. For H1 FY27, revenue grew 30.2% to ₹2,773.1 crore. The company approved a new ~500-bed hospital in Ghaziabad.
The significant revenue and profit growth, coupled with strategic expansion plans like the new Ghaziabad hospital and operational improvements (Noida hospital achieving breakeven), are material positive developments for the company and its stakeholders.
The company reported strong year-on-year growth in revenue, operating EBITDA, and profit after tax for both the quarter and half-year periods. Expansion plans, including a new hospital in Ghaziabad, indicate positive future outlook.
Global Health Limited (Medanta) announced its unaudited consolidated financial results for the second quarter and six-month period ended September 30, 2026. The company reported a significant increase in revenue from operations, reaching ₹14,690 million (₹1469 crore) in Q2 FY27, a 33.6% year-on-year growth. Operating EBITDA surged by 60.2% to ₹3,701 million (₹370.1 crore) with improved margins of 25.2% compared to 21.0% in Q2 FY26. Profit after tax stood at ₹2,191 million (₹219.1 crore), an increase of 38.3% year-on-year.
For the half-year ended September 30, 2026 (H1 FY27), revenue from operations grew by 30.2% year-on-year to ₹27,731 million (₹2773.1 crore). Operating EBITDA increased by 43.4% to ₹6,568 million (₹656.8 crore) with margins improving to 23.7% from 21.5% in H1 FY26. Profit after tax for H1 FY27 was ₹3,764 million (₹376.4 crore), an 18.6% increase year-on-year.
During Q2 FY27, Medanta added 74 new beds across its network, with 49 in Noida and 25 in Lucknow. The Noida hospital, which commenced operations less than a year ago, achieved EBITDA breakeven in Q2 FY27. The company's board also approved the development of a new approximately 500-bedded super-specialty hospital in Ghaziabad, with an estimated capital expenditure of approximately ₹9,970 million (₹997 crore). The company has a net cash surplus of ₹7,815 million (₹781.5 crore) as of September 30, 2026.
Mr. Pankaj Sahni, Group CEO and Director, commented, "We are pleased to report strong growth in Q2 and H1 FY27, driven by robust patient volumes. We continue to deliver steady growth as we expand our bed capacity across multiple locations to meet India's growing need for quality healthcare." The company highlighted strong volume growth, with inpatient count increasing by 29.5% and outpatient count by 37.9% year-on-year.
What to do with a filing like this
Global Health Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Global Health Limited. Read the original for the full detail.